TGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TG Therapeutics Inc (TGTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong revenue growth, other financial metrics such as net income, EPS, and gross margin have declined. Technical indicators suggest the stock is overbought, and there are no significant positive catalysts or proprietary trading signals to justify immediate action. Holding or waiting for a better entry point is advisable.
The MACD histogram is positive at 0.317 but contracting, indicating weakening momentum. RSI is at 80.817, signaling an overbought condition. Moving averages are converging, showing no clear trend. Key resistance levels are at 34.798 and 35.763, with support at 33.238 and 31.678. Pre-market price is slightly down (-0.43%), trading at $34.48.
Revenue growth of 78% YoY in Q4 2025 indicates strong top-line performance.
Declines in net income (-1.26% YoY), EPS (-6.67% YoY), and gross margin (-6.51% YoY). Overbought RSI and lack of significant insider or hedge fund activity. No recent news or congress trading data.
In Q4 2025, revenue increased significantly by 78% YoY to $192.57 million. However, net income dropped by 1.26% YoY to $23.04 million, EPS fell by 6.67% YoY to $0.14, and gross margin declined by 6.51% YoY to 80.19%.
JPMorgan analyst Brian Cheng recently lowered the price target from $49 to $46 while maintaining an Overweight rating, reflecting cautious optimism.
